Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

48.5K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
48.5K
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

441
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
441
Size and Structure of Viral Genomes01:26

Size and Structure of Viral Genomes

441
Viral genomes exhibit remarkable diversity in size, structure, and composition, influencing their replication strategies and interactions with host cells. These genomes consist of either DNA or RNA and may be linear or circular. Additionally, they can be single-stranded or double-stranded, with each configuration affecting how the virus propagates within a host. RNA viruses, for instance, generally have smaller genomes than DNA viruses, a factor that contributes to their high mutation rates and...
441

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conservation of Bacterial Lipopolysaccharide Binding by SARS-CoV-2 Spike across Major Viral Variants.

Computational and structural biotechnology journal·2026
Same author

Multiscale Simulations and Cryo-Electron Microscopy Reveal the Transition Pathway of Dengue Virus-like Particle Nanoassembly.

ACS nano·2026
Same author

The Inlet, Outlet, and New Ratchet Element for Proton Transfer of the <i>Acinetobacter baumannii</i> F-ATP Synthase and Their Critical Role for Viability.

ACS infectious diseases·2025
Same author

Microplastics in human body: accumulation, natural clearance, and biomedical detoxification strategies.

Biomedical engineering letters·2025
Same author

How the Universal MSA52 Aptamer Recognizes the SARS-CoV‑2 Spike Protein.

ACS omega·2025
Same author

Glycans on non-structural protein 1 prevent premature T-cell mediated dengue virus clearance.

EMBO molecular medicine·2025

Related Experiment Video

Updated: Nov 25, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.8K

An Alternative HIV-1 Non-Nucleoside Reverse Transcriptase Inhibition Mechanism: Targeting the p51 Subunit.

Kwok-Fong Chan1, Chinh Tran-To Su1,2, Alexander Krah1

  • 1Bioinformatics Institute, A*STAR, 30 Biopolis Street, #07-01 Matrix, Singapore 138671, Singapore.

Molecules (Basel, Switzerland)
|December 16, 2020
PubMed
Summary

Researchers discovered novel chemical scaffolds that inhibit HIV-1 Reverse Transcriptase (RT) by binding to a new site on the p51 subunit. This offers a potential new strategy for developing drugs against HIV.

Keywords:
HIVNNRTIsdrug resistancenovel p51 drug target

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.2K
Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors
08:33

Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors

Published on: January 19, 2015

9.1K

Related Experiment Videos

Last Updated: Nov 25, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.8K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.2K
Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors
08:33

Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors

Published on: January 19, 2015

9.1K

Area of Science:

  • Virology
  • Medicinal Chemistry
  • Structural Biology

Background:

  • HIV drug resistance necessitates novel therapeutic targets.
  • HIV Reverse Transcriptase (RT) is a critical enzyme in the viral life cycle and a validated drug target.
  • Existing non-nucleoside RT inhibitors (NNRTIs) face challenges due to resistance development.

Purpose of the Study:

  • To identify novel chemical scaffolds that inhibit HIV-1 RT activity.
  • To explore a potential new druggable site on the HIV-1 RT p51 subunit.
  • To investigate a new allosteric mechanism for inhibiting HIV-1 RT.

Main Methods:

  • Screening of the National Cancer Institute (NCI) Diversity Set V for HIV-1 RT inhibitors.
  • Computational structural analyses to determine binding sites.
  • Experimental validation of identified chemical scaffolds and their binding interactions.

Main Results:

  • Two chemical scaffolds were identified that inhibit HIV-1 RT catalytic activity.
  • One scaffold binds to a novel site on the HIV-1 RT p51 subunit, interacting with residue Y183.
  • This interaction is distinct from known drug resistance-associated sites.

Conclusions:

  • A novel druggable site on the HIV-1 RT p51 subunit has been identified.
  • The findings support the development of a new class of allosteric NNRTIs.
  • These scaffolds serve as a proof-of-concept for targeting this novel site, with potential for optimization through medicinal chemistry.